Literature DB >> 19355965

Desferrioxamine as immunomodulatory agent during microorganism infection.

A Williams1, D Meyer.   

Abstract

Southern Africa is burdened with Human Immunodeficiency Virus (HIV) and Mycobacterium tuberculosis (M.tuberculosis) infections as well as conditions of iron (Fe) overload. Highly Active Antiretroviral Therapy (HAART) is used to treat HIV-infection, many drugs exist for the treatment of tuberculosis (new solutions are also being sought because of the existence of multi drug resistant strains of M.tuberculosis) and Fe chelators are commonly used to treat Fe overload. Chelators have also been shown to inhibit the multiplication of numerous microorganisms and hence there are publications suggesting a role for chelators like desferrioxamine (DFO) in the dual treatment of microorganism infection and excess iron. Excess iron fuels pathogen survival which in turn lowers host cell functionality (manifested as altered proliferation, cytokine secretion, etc); withholding iron (via a chelator) reverses the process, even more so when the cells are chelated for longer periods of time. Chelation with DFO is reviewed here by commenting on its immunomodulatory effect.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19355965     DOI: 10.2174/138161209787846801

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  6 in total

Review 1.  Potential Anti-SARS-CoV-2 Therapeutics That Target the Post-Entry Stages of the Viral Life Cycle: A Comprehensive Review.

Authors:  Rami A Al-Horani; Srabani Kar
Journal:  Viruses       Date:  2020-09-26       Impact factor: 5.048

Review 2.  The beneficial role of Hepcidin peptide inhibitor in improved the symptoms of COVID-19 in diabetics: anti-inflammatory and potential therapeutic effects.

Authors:  Motahareh Zeinivand; Nida Jamali-Raeufy; Fahime Zavvari
Journal:  J Diabetes Metab Disord       Date:  2022-07-06

3.  Deferoxamine compensates for decreases in B cell counts and reduces mortality in enterovirus 71-infected mice.

Authors:  Yajun Yang; Jing Ma; Jinghui Xiu; Lin Bai; Feifei Guan; Li Zhang; Jiangning Liu; Lianfeng Zhang
Journal:  Mar Drugs       Date:  2014-07-07       Impact factor: 5.118

4.  Commentary: Could iron chelators prove to be useful as an adjunct to COVID-19 Treatment Regimens?

Authors:  Maria Dalamaga; Irene Karampela; Christos S Mantzoros
Journal:  Metabolism       Date:  2020-05-08       Impact factor: 8.694

5.  Iron overload and Hepcidin overexpression could play a key role in COVID infection, and may explain vulnerability in elderly, diabetics, and obese patients.

Authors:  Filippo Banchini; Daniele Vallisa; Pietro Maniscalco; Patrizio Capelli
Journal:  Acta Biomed       Date:  2020-09-07

Review 6.  Deferoxamine B: A Natural, Excellent and Versatile Metal Chelator.

Authors:  Denise Bellotti; Maurizio Remelli
Journal:  Molecules       Date:  2021-05-28       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.